Access this stock data via API
Subscribe
Innovent Biologics Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is CNY
Fiscal date 2024 2023 2022 2021
Total reported revenue 10.4B 6.9B 5.0B 4.3B
Cost of revenue 1.7B 1.3B 1.0B 505.3M
Gross profit 8.7B 5.6B 4.0B 3.8B
Operating expense
Research & development 3.0B 2.5B 3.1B 2.3B
Selling general and admin 5.6B 4.3B 3.7B 3.4B
Other operating expenses
Operating income 284.9M -1.0B -2.8B -1.9B
Non operating interest income
Income 467.4M 499.8M 207.1M 151.8M
Expense 74.7M 108.9M 111.1M 62.5M
Other income expense
Pretax income -86.8M -1.3B -2.4B -2.6B
Tax provision 17.7M -128.6M 9.6M 87.0M
Net income -104.5M -1.1B -2.4B -2.7B
Basic EPS -0.1 -0.7 -1.5 -1.9
Diluted EPS -0.1 -0.7 -1.5 -1.9
Basic average shares 1.8B 1.7B 1.6B 1.4B
Diluted average shares 1.8B 1.7B 1.6B 1.4B
EBITDA 279.0M -762.2M -1.9B -2.5B
Net income from continuing op. -86.8M -1.3B -2.4B -2.6B
Minority interests
Preferred stock dividends 0 0 0 0
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Pre-market opens in 15 hours 23 minutes

17:36
00:00
09:30
16:00
23:59

Trading Hours (Monday - Friday):

Pre-market
09:00 - 09:30
Main market
09:30 - 16:00
Post-market
16:00 - 16:10
All times are displayed in the Asia/Hong_Kong timezone (HKT, UTC+08:00).